There are 2137 resources available
1365P - A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Presenter: Rintaro Noro
Session: E-Poster Display
Resources:
Abstract
1366P - Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
Presenter: Ruifen Tian
Session: E-Poster Display
Resources:
Abstract
1367P - Treatment duration and adherence in ALK+ non-small cell lung cancer patients treated with brigatinib following prior ALK TKI therapy in the US
Presenter: Huamao Lin
Session: E-Poster Display
Resources:
Abstract
1368P - Lorlatinib in pretreated ALK/ROS1-positive non-small cell lung cancer (NSCLC): Results from the German early access program
Presenter: Nikolaj Frost
Session: E-Poster Display
Resources:
Abstract
1369P - EGFR T790M ctDNA abundance and TP53 co-mutation by next generation sequencing predicted clinical outcomes of osimertinib in non-small cell lung cancer patients from a real-world study
Presenter: Tao Tian
Session: E-Poster Display
Resources:
Abstract
1370P - PD-L1 expression as a predictive biomarker for chemotherapy response in metastatic non-small cell lung cancer (mNSCLC)
Presenter: Rachel Woodford
Session: E-Poster Display
Resources:
Abstract
1371P - Randomized phase II trial of pemetrexed with or without bevacizumab maintenance after cisplatin, pemetrexed and bevacizumab in advanced non-squamous, non-small cell lung cancer (TORG1321)
Presenter: Tetsuro Kondo
Session: E-Poster Display
Resources:
Abstract
1372P - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Presenter: Christian Grohé
Session: E-Poster Display
Resources:
Abstract
1373P - Difference in nephrotoxicity caused by cisplatin after a short or long hydration scheme in non-small cell lung cancer: A retrospective cohort study (HYCIS-XL)
Presenter: Kelly Niggebrugge-Mentink
Session: E-Poster Display
Resources:
Abstract
1374P - Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence
Presenter: Daniel C. Christoph
Session: E-Poster Display
Resources:
Abstract